Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 21 X posts from 15 X users, with an upper bound of 55,365 followers.

RT @VivekSubbiah: Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase I…

RT @VivekSubbiah: Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase I…

RT @VivekSubbiah: Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase I…

RT @VivekSubbiah: Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase I…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 17 additional X posts.